RecruitingPhase 2NCT07333716

Desloratadine in Patients With Ulcerative Colitis

Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis


Sponsor

Tanta University

Enrollment

44 participants

Start Date

Jan 26, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether desloratadine — a common allergy medication (antihistamine) — can help reduce inflammation and improve symptoms in patients with mild-to-moderate ulcerative colitis (an inflammatory bowel disease). **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with mild or moderate active ulcerative colitis - You are currently being treated with mesalamine (5-aminosalicylic acid) **You may NOT be eligible if...** - You have severe ulcerative colitis - You have significant liver or kidney problems - You are pregnant or breastfeeding - You are taking steroids, immunosuppressants, or biologic therapies for your colitis - You are allergic to desloratadine - You have had colon cancer or part of your colon removed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDesloratadine

mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.

DRUGmesalamine

mesalamine 1000 mg three times daily for 3 months


Locations(1)

Menofia university Hospitals

Shibīn al Kawm, Menofia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07333716


Related Trials